Skip to main content
. 2022 Aug 11;7(4):100553. doi: 10.1016/j.esmoop.2022.100553

Figure 1.

Figure 1

Overview of management of T-DXd-related adverse events.

5-HT3, serotonin type 3; DEX, dexamethasone; G-CSF, granulocyte colony-stimulating factor; ILD, interstitial lung disease; i.m., intramuscular; i.v., intravenous; LVEF, left ventricular ejection fraction; NK1, neurokinin-1; p.o., by mouth; RA, receptor antagonist; T-DXd, trastuzumab deruxtecan.